Hunan Hansen Pharmaceutical Co Ltd (SHE:002412) — Market Cap & Net Worth
Market Cap & Net Worth: Hunan Hansen Pharmaceutical Co Ltd (002412)
Hunan Hansen Pharmaceutical Co Ltd (SHE:002412) has a market capitalization of $665.65 Million (CN¥4.55 Billion) as of September 19, 2026. Listed on the SHE stock exchange, this China-based company holds position #10898 globally and #3012 in its home market, demonstrating a -0.11% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Hunan Hansen Pharmaceutical Co Ltd's stock price CN¥9.04 by its total outstanding shares 503200000 (503.20 Million). Also see 002412 current and non-current assets for a full breakdown of the balance sheet.
Hunan Hansen Pharmaceutical Co Ltd Market Cap History: 2015 to 2026
Hunan Hansen Pharmaceutical Co Ltd's market capitalization history from 2015 to 2026. Data shows change from $1.05 Billion to $665.65 Million (-3.26% CAGR). Also see 002412 operating cash flow for how efficiently the company converts equity into cash flow.
Hunan Hansen Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Hunan Hansen Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Hunan Hansen Pharmaceutical Co Ltd stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.45x
Hunan Hansen Pharmaceutical Co Ltd's market cap is 0.45 times its annual revenue
Latest Price to Earnings (P/E) Ratio
2.38x
Hunan Hansen Pharmaceutical Co Ltd's market cap is 2.38 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $722.81 Million | $798.47 Million | $84.94 Million | 0.91x | 8.51x |
| 2017 | $678.91 Million | $829.94 Million | $108.81 Million | 0.82x | 6.24x |
| 2018 | $582.22 Million | $921.95 Million | $147.54 Million | 0.63x | 3.95x |
| 2019 | $610.85 Million | $887.49 Million | $162.38 Million | 0.69x | 3.76x |
| 2020 | $468.86 Million | $741.24 Million | $106.15 Million | 0.63x | 4.42x |
| 2021 | $447.04 Million | $891.84 Million | $134.85 Million | 0.50x | 3.32x |
| 2022 | $431.55 Million | $916.06 Million | $167.62 Million | 0.47x | 2.57x |
| 2023 | $499.24 Million | $955.53 Million | $205.01 Million | 0.52x | 2.44x |
| 2024 | $442.54 Million | $1.00 Billion | $220.24 Million | 0.44x | 2.01x |
| 2025 | $471.99 Million | $1.04 Billion | $198.12 Million | 0.45x | 2.38x |
Competitor Companies of 002412 by Market Capitalization
Companies near Hunan Hansen Pharmaceutical Co Ltd in the global market cap rankings as of September 19, 2026. Review Hunan Hansen Pharmaceutical Co Ltd (002412) tangible equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Hunan Hansen Pharmaceutical Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #518 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #613 globally with a market cap of $44.92 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #635 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #670 globally with a market cap of $40.99 Billion USD ( CN¥280.10 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #518 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #613 | GALDERMA GROUP AG | NYSE:GALDY | $44.92 Billion | $38.53 |
| #635 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.90 |
| #670 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $40.99 Billion | CN¥43.91 |
Hunan Hansen Pharmaceutical Co Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Hunan Hansen Pharmaceutical Co Ltd's market cap moved from $1.05 Billion to $ 665.65 Million, with a yearly change of -3.26%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥665.65 Million | +41.03% |
| 2025 | CN¥471.99 Million | +6.66% |
| 2024 | CN¥442.54 Million | -11.36% |
| 2023 | CN¥499.24 Million | +15.69% |
| 2022 | CN¥431.55 Million | -3.47% |
| 2021 | CN¥447.04 Million | -4.65% |
| 2020 | CN¥468.86 Million | -23.24% |
| 2019 | CN¥610.85 Million | +4.92% |
| 2018 | CN¥582.22 Million | -14.24% |
| 2017 | CN¥678.91 Million | -6.07% |
| 2016 | CN¥722.81 Million | -31.29% |
| 2015 | CN¥1.05 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 19th, 2026 the market cap of Hunan Hansen Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $665.65 Million USD |
| MoneyControl | $665.65 Million USD |
| MarketWatch | $665.65 Million USD |
| marketcap.company | $665.65 Million USD |
| Reuters | $665.65 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Hunan Hansen Pharmaceutical Co Ltd
Hunan Hansen Pharmaceutical Co., Ltd. engages in the production and sale of traditional Chinese preparations in China and internationally. The company offers medications for digestive, cardiovascular, cerebrovascular, and urological diseases, as well as for traumatology and diagnostic applications. It provides its products in various forms, including injections, mixtures, tablets, capsules, granu… Read more